Hunan Jingfeng Pharmaceutical - Asset Resilience Ratio
Hunan Jingfeng Pharmaceutical (000908) has an Asset Resilience Ratio of 0.38% as of December 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Hunan Jingfeng Pharmaceutical to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1998–2018)
This chart shows how Hunan Jingfeng Pharmaceutical's Asset Resilience Ratio has changed over time. See 000908 equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Hunan Jingfeng Pharmaceutical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 000908 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥20.00 Million | 0.38% |
| Total Liquid Assets | CN¥20.00 Million | 0.38% |
Asset Resilience Insights
- Limited Liquidity: Hunan Jingfeng Pharmaceutical maintains only 0.38% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hunan Jingfeng Pharmaceutical Industry Peers by Asset Resilience Ratio
Compare Hunan Jingfeng Pharmaceutical's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AstraZeneca PLC
F:ZEGA |
Drug Manufacturers - General | 0.03% |
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 0.10% |
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.48% |
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 5.48% |
|
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
SHE:301096 |
Drug Manufacturers - General | 1.58% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd
SHG:600671 |
Drug Manufacturers - General | 0.81% |
Annual Asset Resilience Ratio for Hunan Jingfeng Pharmaceutical (1998–2018)
The table below shows the annual Asset Resilience Ratio data for Hunan Jingfeng Pharmaceutical.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 0.38% | CN¥20.00 Million ≈ $2.93 Million |
CN¥5.23 Billion ≈ $764.89 Million |
+0.15pp |
| 2016-12-31 | 0.23% | CN¥11.94 Million ≈ $1.75 Million |
CN¥5.13 Billion ≈ $751.27 Million |
+0.21pp |
| 2015-12-31 | 0.02% | CN¥706.00K ≈ $103.31K |
CN¥3.44 Billion ≈ $503.77 Million |
-0.29pp |
| 2009-12-31 | 0.31% | CN¥2.40 Million ≈ $351.20K |
CN¥784.81 Million ≈ $114.84 Million |
+0.21pp |
| 2007-12-31 | 0.10% | CN¥801.34K ≈ $117.26K |
CN¥814.38 Million ≈ $119.17 Million |
+0.06pp |
| 2006-12-31 | 0.04% | CN¥350.00K ≈ $51.22K |
CN¥822.47 Million ≈ $120.35 Million |
-3.49pp |
| 2005-12-31 | 3.53% | CN¥29.66 Million ≈ $4.34 Million |
CN¥840.14 Million ≈ $122.94 Million |
-2.63pp |
| 2004-12-31 | 6.16% | CN¥54.81 Million ≈ $8.02 Million |
CN¥889.56 Million ≈ $130.17 Million |
-10.65pp |
| 2003-12-31 | 16.81% | CN¥165.26 Million ≈ $24.18 Million |
CN¥983.02 Million ≈ $143.85 Million |
+16.63pp |
| 2002-12-31 | 0.18% | CN¥1.57 Million ≈ $229.79K |
CN¥866.67 Million ≈ $126.82 Million |
-8.42pp |
| 2000-12-31 | 8.60% | CN¥60.00 Million ≈ $8.78 Million |
CN¥697.92 Million ≈ $102.13 Million |
-0.07pp |
| 1999-12-31 | 8.67% | CN¥60.00 Million ≈ $8.78 Million |
CN¥691.94 Million ≈ $101.25 Million |
-1.90pp |
| 1998-12-31 | 10.57% | CN¥50.00 Million ≈ $7.32 Million |
CN¥473.15 Million ≈ $69.24 Million |
-- |
About Hunan Jingfeng Pharmaceutical
Hunan Jingfeng Pharmaceutical Co.,Ltd. manufactures and sells chemical drugs and biological agents in China. The company's principal product is sodium hyaluronate injection for use in orthopedics and surgery applications. It also offers ophthalmic equipment and API products, as well as engages in the research and development of antitumor, cancer, and cardiovascular drugs; and distributed in the f… Read more